PCSK9 Inhibitors and CV Risk Reduction

In this two part educational series, entitled PCSK9 inhibitors and CV Risk Reduction: Understanding the Implications, experts discuss how Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors represent a promising strategy for decreasing CV risk in patients. In the first session, Drs. Michael Blaha and Michael Miller discuss The Emerging Role of PCSK9 Inhibitors. In part 2, Drs. Marc S. Sabatine, and James Underberg analyze the PCSK9 Outcome Studies. This series will improve clinician’s knowledge of the updated guidelines and the benefits /risks of newer therapies. It also provides clinicians with the tools to select the optimal LDL-C-lowering regimens, address concerns, and improve adherence, to more effectively lower cardiovascular risk in their patients.